Drugs / AMT-676
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06400485 | Jun 2024 → May 2027 expected | cancer | Multitude Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07474727 | Apr 2026 → Sep 2027 expected | colorectal cancer | Multitude Therapeutics Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMT-676 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06400485 ↗ |
| Modality | Other / unclassified | “an Anti CDH17 Antibody-Drug Conjugate” NCT06400485 ↗ |
| Route | Intravenous | “Participants will receive AMT-676 administered intravenously.” NCT06400485 ↗ |
| Target | CDH17 | “an Anti CDH17 Antibody-Drug Conjugate” NCT06400485 ↗ |